Dessislava Stefanova
Research Subjects
Dessislava Stefanova has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Rasa Zarnegar
Department of Surgery, Weill Cornell Medicine , New York, NY 10065
21 shared publications - Irene M. Min
Department of Radiology, Houston Methodist Research Institute, Houston, Texas
20 shared publications - Moonsoo M. Jin
Department of Radiology, Houston Methodist Research Institute, Houston, Texas
20 shared publications - Thomas J. Fahey
Department of Surgery, Weill Cornell Medical Center, New York, USA
20 shared publications - Maria Cristina Riascos
Department of Pathology, Mass General Brigham
19 shared publications - Yanping Yang
Department of Radiology, Houston Methodist Research Institute, Houston, Texas
19 shared publications
Latest Publications
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
HLA dependence of engineered T-cell populations quantified as Δ target viability
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
HLA dependence of engineered T-cell populations quantified as Δ target viability
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
Phenotypic analysis of engineered T cells
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
Phenotypic analysis of engineered T cells
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S14 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
Phenotypes of RM-ATC and donor-matched primary T cells
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S14 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
Phenotypes of RM-ATC and donor-matched primary T cells
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
Increased NFAT activity mounted by TCR-8505C/ICCR expression
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
Increased NFAT activity mounted by TCR-8505C/ICCR expression
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S12 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
Generation of 8505C-OKT3 cells
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
Generation of 8505C-OKT3 cells
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
TCRa depletion in ICCR-T cells
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
TCRa depletion in ICCR-T cells
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
Conjugate analysis of engineered T cells and IFNγ-prestimulated A375-MA2 cells
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function
Conjugate analysis of engineered T cells and IFNγ-prestimulated A375-MA2 cells
- 8 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (7) , OF1-OF17
An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-Cell Function
Engineered T-cell therapies, such as chimeric antigen receptor (CAR)– and T-cell receptor (TCR)–based approaches, have transformed outcomes in hematologic malignancies, yet their efficacy in solid tumors remains limited by tumor antigen escape, immunosuppressive microenvironments, and insufficient activation of CAR or TCR signaling. To overcome these barriers, we developed an intercellular adhesion molecule 1 (ICAM1)–specific chimeric costimulatory receptor (ICCR) engineered for expression in T cells to augment their activation. ICAM1 is broadly expressed across solid tumors and is further upregulated by IFNγ released during early T-cell engagement, creating a feed-forward loop that reinforces tumor recognition. ICCR engagement with ICAM1 triggered NF-κB signaling independently of TCR–peptide (p)/MHC engagement; however, full T-cell activation and cytotoxic function remained dependent on intact TCR signaling. In primary T cells, ICCR increased proliferation, cytokine production, and cytotoxicity, resulting in improved tumor control in two anaplastic thyroid cancer xenograft models treated with allogeneic or autologous ICCR-T cells. Mechanistically, ICCR strengthened tumor cell engagement, promoted selection and expansion of tumor-specific TCR clonotypes, and amplified downstream signaling pathways. These findings identify ICCR as a strategy that leverages an immune synapse–mimetic mechanism to enhance the function of low-activity tumor-specific TCRs and improve T-cell responses in solid tumor microenvironments.
- 8 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (7) , OF1-OF17
An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-Cell Function
Engineered T-cell therapies, such as chimeric antigen receptor (CAR)– and T-cell receptor (TCR)–based approaches, have transformed outcomes in hematologic malignancies, yet their efficacy in solid tumors remains limited by tumor antigen escape, immunosuppressive microenvironments, and insufficient activation of CAR or TCR signaling. To overcome these barriers, we developed an intercellular adhesion molecule 1 (ICAM1)–specific chimeric costimulatory receptor (ICCR) engineered for expression in T cells to augment their activation. ICAM1 is broadly expressed across solid tumors and is further upregulated by IFNγ released during early T-cell engagement, creating a feed-forward loop that reinforces tumor recognition. ICCR engagement with ICAM1 triggered NF-κB signaling independently of TCR–peptide (p)/MHC engagement; however, full T-cell activation and cytotoxic function remained dependent on intact TCR signaling. In primary T cells, ICCR increased proliferation, cytokine production, and cytotoxicity, resulting in improved tumor control in two anaplastic thyroid cancer xenograft models treated with allogeneic or autologous ICCR-T cells. Mechanistically, ICCR strengthened tumor cell engagement, promoted selection and expansion of tumor-specific TCR clonotypes, and amplified downstream signaling pathways. These findings identify ICCR as a strategy that leverages an immune synapse–mimetic mechanism to enhance the function of low-activity tumor-specific TCRs and improve T-cell responses in solid tumor microenvironments.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-7 from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma
S1. BRAFV600E mutation identified in thyroid cancer cell lines analyzed by RNA-seq.S2. STR analysis in thyroid cancer cell lines used in this study.S3. Gene expression of thyroid-specific genes in thyroid cancer cell lines analyzed by RNA-seq.S4. Dose-dependent toxicity of vemurafenib in BRAFV600E thyroidcancer cells.S5. Vemurafenib dose-dependent curves of vemurafenib-resistantBRAFV600E thyroid cancer cells.S6. Vemurafenib induces apoptosis in 8505C cells.S7. Predicted activators and inhibitors in Vem-resistant BRAF mutant thyroid cancer cells.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-7 from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma
S1. BRAFV600E mutation identified in thyroid cancer cell lines analyzed by RNA-seq.S2. STR analysis in thyroid cancer cell lines used in this study.S3. Gene expression of thyroid-specific genes in thyroid cancer cell lines analyzed by RNA-seq.S4. Dose-dependent toxicity of vemurafenib in BRAFV600E thyroidcancer cells.S5. Vemurafenib dose-dependent curves of vemurafenib-resistantBRAFV600E thyroid cancer cells.S6. Vemurafenib induces apoptosis in 8505C cells.S7. Predicted activators and inhibitors in Vem-resistant BRAF mutant thyroid cancer cells.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-5 from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma
Supplementary Table 1. Gene expression changes in 8505C after vemurafenib treatment.Supplementary Table 2. Gene expression changes in WRO after vemurafenib treatment.Supplementary Table 3. Gene expression changes in 8505C -Vem-Res 1 relative to parental 8505C.Supplementary Table 4. Gene expression changes in WRO -Vem-Res 6 relative to parental WRO.Supplementary Table 5. Clinical features of thyroid tumors used in Fig. 5.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-5 from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma
Supplementary Table 1. Gene expression changes in 8505C after vemurafenib treatment.Supplementary Table 2. Gene expression changes in WRO after vemurafenib treatment.Supplementary Table 3. Gene expression changes in 8505C -Vem-Res 1 relative to parental 8505C.Supplementary Table 4. Gene expression changes in WRO -Vem-Res 6 relative to parental WRO.Supplementary Table 5. Clinical features of thyroid tumors used in Fig. 5.